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Abstract  Hypersplenism  is  excess  activity  of  the  spleen,  resulting  in  peripheral  pancytopenia
that predominates  in  platelet  cell  lines.  Pancytopenia  can  be  limited  by  reducing  the  volume
of the  functional  spleen.  However,  in  patients  in  very  poor  general  condition,  a  splenectomy
may not  be  possible,  due  to  the  risks  of  surgery  and  postoperative  infection.  Another  thera-
peutic alternative  in  these  patients  is  to  reduce  the  volume  of  the  spleen  by  super  selective
percutaneous  splenic  embolization.  We  report  three  cases  of  peripheral  thrombocytopenia
due to  hypersplenism  with  a  platelet  count  between  60,000  and  80,000/mm3,  which  made  it
impossible  to  continue  or  start  a  chemotherapy  protocol  in  these  patients.  For  these  patients,
super selective  partial  embolization  of  the  splenic  parenchyma,  with  uncharged  microspheres
(250 microns)  quickly  resulted  in  a  platelet  count  above  150,000/mm3 so  that  chemotherapy
could be  continued  or  initiated.
© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.Thrombocytopenia  is  deﬁned  as  a  platelet  count  below  150,000/mm3.  One  of  the  eti-
ologies  is  splenic  sequestration  due  to  portal  hypertension.  If  drug  treatments  are
unsuccessful,  splenectomy  is  often  considered  as  a  last  resort  to  treat  refractory
thrombocytopenias.  However,  surgical  treatment  has  both  perioperative  and  post-
operative  risks  [1,2]. Moreover,  in  patients  in  poor  condition  who  cannot  support
general  anesthesia,  splenectomy  is  often  contra-indicated  and  dangerous.  Partial  splenic
embolization  (PSE)  may  be  an  interesting  alternative  in  these  cases  [3,4].  PSE  is
a  non-surgical  procedure  performed  in  the  interventional  radiology  procedure  room,
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Figure 1. Coronal abdominopelvic CT with contrast injection dur-
ing the portal phase 2 months after splenic embolization showing
splenomegaly with a large unenhanced area of liquid (arrow) rep-
resenting an area of splenic necrosis. The functional parenchyma
is enhanced after contrast injection (asterisk). Ischemia involves
approximately 70% of the splenic parenchyma but does not include
the superior pole of the spleen to prevent post-embolization pleural
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count  of  80,000/mm3 contra-indicating  antiangiogenics  and
participation  in  a  new  therapeutic  trial  because  of  tumor84  
hich  avoids  the  disadvantages  of  splenectomy,  in  partic-
lar,  the  risk  of  infection.  We  report  three  different  cases
hat  have  the  following  points  in  common:  all  patients  had
ancer  and  thrombocytopenia  due  to  hypersplenism  making
t  impossible  to  begin  or  continue  a  chemotherapy  proto-
ol.  The  goal  of  our  study  was  to  describe  the  role  of  partial
uperselective  splenic  embolization,  which  rapidly  resulted
n  an  acceptable  platelet  count  allowing  chemotherapy  to
e  continued  or  begun  in  these  patients.
linical cases
ase 1
 46-year-old  patient  had  been  followed  since  2001  for
ntrahepatic  cholangiocarcinoma  that  had  been  treated  by  a
ight  hepatectomy  that  was  extended  to  segment  IV.  In  2012,
holangiocarcinoma  recurred  and  was  exclusively  intra-
eptatic.  Hypersplenism  was  identiﬁed  during  the  initial
ssessment  before  treatment  was  decided,  associated  with
hrombocytopenia  with  a  platelet  count  of  80,000/mm3,
hich  was  probably  secondary  to  the  right  hepatec-
omy.  Antiangiogenic  treatment  was  contra-indicated  in  this
atient  due  to  thrombocytopenia.
Because  of  the  patient’s  general  condition,  PSE  was
ecided  during  the  pluridisciplinary  consensus  meeting  with
he  goal  of  correcting  thrombocytopenia  to  reach  a  count  of
ore  than  120,000/mm3.
After  careful  skin  preparation  and  local  anesthesia,  a
emoral  approach  was  taken.  The  celiac  trunk  and  the
plenic  arterty  were  catheterized  with  a  5F  catheter  with
 cobra  head  and  a  ﬂexible  guide.  Embolization  of  the
ranches  of  the  splenic  artery  was  performed  at  the  inferior
ole  and  the  middle  third  with  a  microcatheter.  Uncharged
50  micron  microspheres  (Embozene,  CeloNova  BioSciences,
eadquarters  San  Antonio,  Texas,  USA)  were  used  for
mbolization.  Final  follow-up  showed  signiﬁcant  stagnation
f  the  contrast  agent  in  the  middle  and  lower  territories
f  the  splenic  parenchyma.  The  patient  was  hospitalized
or  48  hours  after  the  procedure  to  treat  post-embolization
yndrome.
Seven  days  after  embolization,  control  CT  showed  splenic
schemia  of  between  50  and  70%,  which  corresponds  to  the
oals  in  the  literature  (Fig.  1)  [3,4].
Ten  days  after  embolization,  a  control  visit  showed  a
latelet  count  of  162,000/mm3 so  that  systemic  treatment
ould  be  begun.  The  patient  presented  with  left  upper
uadrant  pain  for  48  hours  after  embolization  that  was  suc-
essfully  treated  by  morphine,  with  no  other  adverse  effects
eported.
ase 2
 50-year-old  man  was  being  followed  for  adenocarcinoma
f  the  recto-sigmoïd  junction,  classiﬁed  as  T4  N1  M0,  and
hich  was  discovered  during  investigation  of  occlusion.
anagement  included  subtotal  colectomy  with  an  ileorectal
nastomosis  and  lymph  node  dissection  associated  with  FOL-
OX  (oxaliplatin,  5  ﬂuoro-uracile,  acide  folinique)  adjuvant
hemotherapy.  At  2  months,  unresectable  metachronous
iver  metastases  developed.  Chemotherapy  was  modiﬁed  to
p
o
teactions.
 Folfox—Avastin  regimen  (a  total  of  23  rounds).  The  patient
hen  developed  portal  hypertension  with  thrombocytopenia
nd  a  platelet  count  of  60,000/mm3 contra-indicating  the
se  of  antiangiogenics  and  participation  in  a  new  treatment
rotocol.  It  was  then  decided  to  treat  the  thrombocytopenia
ith  selective  PSE.  Embolization  was  identical  to  that  in
ase  1,  with  no  complications.
One  month  after  embolization,  the  platelet  count  had
eached  200,000/mm3,  so  the  patient  could  participate
n  a  clinical  trial  that  included  angiogenics.  At  2  months,
ontrol  CT  showed  spenic  ischemia  of  50—70%  of  the
arenchyma.  At  4  months,  the  platelet  count  remained  sta-
le  at  120,000/mm3 but  secondary  pulmonary  and  vertebral
esions  developed  causing  sleep  disturbing  pain  that  did  not
espond  to  analgesics.
ase 3
 42-year-old  patient  had  been  followed  since  February  2012
or  an  adenocarcinoma  of  the  left  colon  with  synchronous
iver  metastases.  Management  included  a  left  colectomy,
esection  of  a  left  liver  metastasis  and  radiofrequency  abla-
ion.  Total  portal  vein  thrombosis  developed  after  surgery.
Two  months  after  surgery,  recurrent  liver  metastases  and
econdary  pulmonary  lesions  developed.  Chemotherapy  with
 Folﬁri-Avastin  regimen  was  decided  upon.  The  patient  then
eveloped  portal  hypertension  on  the  thrombosis  result-
ng  in  hypersplenism  with  thrombocytopenia  and  a  plateletrogression.  PSE  was  decided  upon  to  reach  a  platelet  count
f  120,000/mm3 and  to  include  the  patient  in  a  therapeutic
rial.
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Embolization  was  identical  to  that  in  case  1,  with  no
complications  and  resulted  in  70%  splenic  ischemia.
The  postoperative  outcome  included  pain  that  was  resis-
tant  to  level  3  (morphine-based)  analgesics  as  well  as  39◦
hyperthermia  for  48  h.
Fifteen  days  after  surgery,  the  platelet  count  had  stabi-
lized  at  530,000/mm3 so  that  antiangiogenic  therapy  was
begun  again  and  the  patient  could  be  included  in  a new
therapeutic  trial.
Discussion
This  report  is  original  because  the  origin  of  portal  hyper-
tension  in  these  patients  was  non-cirrhotic.  Indeed,  to  our
knowledge,  this  is  the  ﬁrst  report  of  PSE  for  a  palliative  onco-
logical  indication  with  no  underlying  chronic  liver  disease.
Hypersplenism  is  a  well-known  complication  of  portal  hyper-
tension.  This  may  be  present  as  thrombocytopenia  and/or
leukocytopenia.  In  certain  patients  with  severe  peripheral
cytopenia,  treatments  such  as  interferon  [5],  antiangiogen-
ics  [6],  and  major  surgery  [7]  can  be  contra-indicated  and
can,  therefore,  be  the  cause  of  a  loss  of  chance  for  patients.
Moreover,  life-threatening  spontaneous  episodes  of  bleed-
ing  may  also  occur  in  these  patients  who  are  already  in  poor
condition.
Portal  hypertension  with  hypersplenism  has  many  pos-
sible  causes:  prehepatic  portal  hypertension  is  caused  by
obstruction  of  the  portal  venous  system  (by  compression,
tumor  invasion  or  thrombosis).  Intrahepatic  portal  hyper-
tension  can  be  sinusoidal,  or  post-sinusoidal  but  in  fact,
it  is  often  mixed.  Sinusoidal  portal  hypertension  is  mainly
due  to  cirrhosis,  which  accounts  for  90%  of  the  causes
of  portal  hypertension  in  western  countries.  Post-hepatic
portal  hypertension  is  mainly  secondary  to  Budd-Chiari  syn-
drome.  In  the  present  study,  we  present  a  case  of  iatrogenic
intrahepatic  portal  hypertension  secondary  to  oxaliplatin
[8].  This  adverse  effect  has  been  described  in  the  litera-
ture  by  numerous  authors  [9]  but  the  physiopathology  is
still  a  subject  of  debate.  Nevertheless,  there  is  no  oxa-
liplatin  dose  limit  for  the  moment  to  limit  this  adverse
effect.
In  case  1,  the  cause  of  portal  hypertension  was  a  par-
tial  hepatectomy  in  a  patient  with  liver  metastases.  Portal
hypertension  is  a  well-known  complication  of  this  type  of
surgery  [10].
At  present,  a  surgical  splenectomy  is  the  reference  tech-
nique  for  reducing  splenic  cell  hyperdestruction  and  treating
cases  of  peripheral  thrombocytopenia  that  do  not  respond  to
medical  treatment.  However,  complications  are  severe  with
this  type  of  surgery  and  occur  in  9.6  to  26.6%  of  the  cases
including  those  performed  by  laparoscopy  [1,2].  Moreover,
splenectomy  is  often  associated  with  an  increased  long-term
risk  of  septic  events  [1,2],  in  particular  encapsulated  orga-
nisms  such  as  pneumococcus  or  meningococcus.
Partial  splenic  embolization  was  ﬁrst  described  by  Mad-
dison  in  1973  [11],  and  was  proposed  as  an  effective
alternative  to  splenectomy  [12,13].  Several  studies  have
shown  that  this  procedure  is  feasible  and  reported  effective
results  in  particular  in  patients  with  cirrhosis,  with  a  sig-
niﬁcant  increase  in  both  the  platelet  and  leucocyte  count
[9,12—14].
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The  volume  of  the  splenic  infarction  is  an  essential  fac-
or  for  long-term  improvement  in  thrombocytopenia,  and  it
hould  be  between  50  and  70%  [3,4], to  ensure  effective
ong-term  management  of  hypersplenism  and  reduce  severe
omplications  such  as  splenic  abscess  or  rupture,  refractory
scites  or  pleural  effusion  [3,15,16].  No  speciﬁc  precautions
gainst  infection  are  needed  with  partial  splenic  emboliza-
ion:  no  pneumococcal  vaccination  or  speciﬁc  long-term
ntibiotics  are  needed,  unlike  with  splenectomy.
The  patients  in  the  present  study  were  all  late  stage,
equiring  palliative  treatment  and  in  poor  general  condi-
ion.  Successful  management  of  their  thrombocytopenia
as  essential  to  give  them  access  to  treatment  and  to
articipation  in  treatment  protocols.  However,  a  splenec-
omy  was  impossible  because  of  their  general  condition  and
omorbidities.  The  indication  of  PSE  was,  therefore,  a  good
lternative  to  splenectomy  for  the  treatment  of  refractory
hrombocytopenia  with  portal  hypertension.
Morbidity  following  PSE  is  low  with  severe  complications
n  less  than  10%  and  mortality  in  less  than  1%  compared
o  5%  for  splenectomy  [17].  The  main  complications  fol-
owing  PSE  were  left  subphrenic  abscess,  splenic  rupture,
cute  pancreatitis,  reactional  pleural  effusion  and  throm-
osis  of  the  splenic  or  portal  veins.  The  rate  of  severe
omplications  varies  in  relation  to  the  volume  of  splenic
nfarction  [3,4].  If  it  is  more  than  70%  of  the  splenic  vol-
me,  severe  complications  develop  in  50%  compared  to  8.8%
f  the  infarctus  is  between  50%  and  70%.  In  these  patients
ho  require  palliative  treatment,  the  risk-beneﬁt  ratio
learly  seems  to  support  PSE.  It  is  associated  with  very  few
dverse  events  and  makes  it  possible  for  patients  to  receive
hemotherapy  which  increases  their  life  expectancy  and
uality  of  life.  The  context  of  palliative  care  is  especially
nteresting  because  this  procedure  is  easy  to  perform  under
ocal  anesthesia  and  has  immediate,  long-term  effects.  In
he  three  reported  cases,  the  PSE  restored  the  platelet
ount  enough  to  allow  appropriate  systemic  treatment,  with
o  serious  complications  from  the  procedure.
Uncharged  microparticles  such  as  microspheres  were
hosen  in  this  study  for  embolization.  Proximal  agents
coils,  plugs  or  balloons)  result  in  occlusion  of  the  splenic
rtery  but  with  minimal  change  in  the  splenic  parenchyma
nless  the  collateral  network  is  affected.  The  goal  of
his  treatment  is  to  superselectively  destroy  part  of  the
plenic  parenchyma;  the  intraparenchymatous  branches  of
he  splenic  artery  must,  therefore,  be  occluded  as  dis-
ally  as  possible.  Agents  causing  distal  embolization  such  as
icroparticles  or  resorbable  gelatin  can  therefore  be  used.
ccording  to  Zhu  et  al.  [3], microparticles  are  more  effec-
ive  than  absorbable  gelatin  in  increasing  the  platelet  count,
ith  no  difference  in  the  rate  of  complications.  Two  hundred
nd  ﬁfty  micron  microspheres  were  therefore  used.
The  good  results  of  PSE  in  patients  with  palliative  stage
isease  must  be  conﬁrmed  in  a  larger  group  of  patients
o  better  evaluate  the  rate  of  efﬁcacy  and  potential
omplications.onclusion
n  conclusion,  partial  splenic  embolization  successfully
reated  refractory  thrombocytopenia  in  three  patients
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resenting  with  portal  hypertension  secondary  to  late  stage
eoplastic  liver  disease  requiring  palliative  treatment.  Thus,
artial  splenic  embolization  seems  to  be  a  viable  option  for
he  treatment  of  refractory  thrombocytopenia  in  patients
ith  late  stage  disease  requiring  palliative  care,  which  does
ot  require  a  pneumococcal  vaccination  or  long  term  antibi-
tics.
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